Literature DB >> 20071518

Constitutive genetic deletion of the growth regulator Nogo-A induces schizophrenia-related endophenotypes.

Roman Willi1, Oliver Weinmann, Christine Winter, Julia Klein, Reinhard Sohr, Lisa Schnell, Benjamin K Yee, Joram Feldon, Martin E Schwab.   

Abstract

The membrane protein Nogo-A, which is predominantly expressed by oligodendrocytes in the adult CNS and by neurons mainly during development, is well known for limiting neurite outgrowth and regeneration in the injured mammalian CNS. In addition, it has recently been proposed that abnormal Nogo-A expression or Nogo receptor (NgR) mutations may confer genetic risks for neuropsychiatric disorders of presumed neurodevelopmental origin, such as schizophrenia. We therefore evaluated whether Nogo-A deletion may lead to schizophrenia-like abnormalities in a mouse model of genetic Nogo-A deficiency. Here, we show that systemic, lifelong knock-out of the Nogo-A gene can lead to specific behavioral abnormalities resembling schizophrenia-related endophenotypes: deficient sensorimotor gating, disrupted latent inhibition, perseverative behavior, and increased sensitivity to the locomotor stimulating effects of amphetamine. These behavioral phenotypes were accompanied by altered monoaminergic transmitter levels in specific striatal and limbic structures, as well as changes in dopamine D2 receptor expression in the same brain regions. Nogo-A deletion was further associated with elevated expression of growth-related markers. In contrast, acute antibody-mediated Nogo-A neutralization in adult wild-type mice failed to produce such phenotypes, suggesting that the phenotypes observed in the knock-out mice might be of developmental origin, and that Nogo-A normally subserves critical functions in neurodevelopment. This study provides the first experimental demonstration that Nogo-A bears neuropsychiatric relevance, and alterations in its expression may be one etiological factor in schizophrenia and related disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20071518      PMCID: PMC6633005          DOI: 10.1523/JNEUROSCI.4393-09.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  83 in total

Review 1.  Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.

Authors:  A Carlsson; N Waters; S Holm-Waters; J Tedroff; M Nilsson; M L Carlsson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

Review 2.  Catching up on schizophrenia: natural history and neurobiology.

Authors:  D A Lewis; J A Lieberman
Journal:  Neuron       Date:  2000-11       Impact factor: 17.173

3.  Schizophrenia: more dopamine, more D2 receptors.

Authors:  P Seeman; S Kapur
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

4.  Dissociative effects of apomorphine infusions into the medial prefrontal cortex of rats on latent inhibition, prepulse inhibition and amphetamine-induced locomotion.

Authors:  L M Broersen; J Feldon; I Weiner
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

Review 5.  The neuropathology of schizophrenia. A critical review of the data and their interpretation.

Authors:  P J Harrison
Journal:  Brain       Date:  1999-04       Impact factor: 13.501

Review 6.  Brain maturational processes and delayed onset in schizophrenia.

Authors:  M S Keshavan; G E Hogarty
Journal:  Dev Psychopathol       Date:  1999

Review 7.  Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies.

Authors:  D L Braff; M A Geyer; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

Review 8.  To model a psychiatric disorder in animals: schizophrenia as a reality test.

Authors:  B K Lipska; D R Weinberger
Journal:  Neuropsychopharmacology       Date:  2000-09       Impact factor: 7.853

9.  The growth-associated protein GAP-43 is increased in the hippocampus and in the gyrus cinguli in schizophrenia.

Authors:  K Blennow; N Bogdanovic; C G Gottfries; P Davidsson
Journal:  J Mol Neurosci       Date:  1999 Aug-Oct       Impact factor: 3.444

10.  Application of neutralizing antibodies against NI-35/250 myelin-associated neurite growth inhibitory proteins to the adult rat cerebellum induces sprouting of uninjured purkinje cell axons.

Authors:  A Buffo; M Zagrebelsky; A B Huber; A Skerra; M E Schwab; P Strata; F Rossi
Journal:  J Neurosci       Date:  2000-03-15       Impact factor: 6.167

View more
  24 in total

Review 1.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

Review 2.  New Insights into the Roles of Nogo-A in CNS Biology and Diseases.

Authors:  Yun-Peng Sui; Xiao-Xi Zhang; Jun-Lin Lu; Feng Sui
Journal:  Neurochem Res       Date:  2015-08-13       Impact factor: 3.996

3.  Mice Lacking the Serotonin Htr2B Receptor Gene Present an Antipsychotic-Sensitive Schizophrenic-Like Phenotype.

Authors:  Pothitos M Pitychoutis; Arnauld Belmer; Imane Moutkine; Joëlle Adrien; Luc Maroteaux
Journal:  Neuropsychopharmacology       Date:  2015-05-04       Impact factor: 7.853

4.  Interaction between amyloid precursor protein and Nogo receptors regulates amyloid deposition.

Authors:  Xiangdong Zhou; Xiangyou Hu; Wanxia He; Xiaoying Tang; Qi Shi; Zhuohua Zhang; Riqiang Yan
Journal:  FASEB J       Date:  2011-06-13       Impact factor: 5.191

Review 5.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

Review 6.  Nogo limits neural plasticity and recovery from injury.

Authors:  Martin E Schwab; Stephen M Strittmatter
Journal:  Curr Opin Neurobiol       Date:  2014-03-12       Impact factor: 6.627

7.  Neutralization of Nogo-A enhances synaptic plasticity in the rodent motor cortex and improves motor learning in vivo.

Authors:  Ajmal Zemmar; Oliver Weinmann; Yves Kellner; Xinzhu Yu; Raul Vicente; Miriam Gullo; Hansjörg Kasper; Karin Lussi; Zorica Ristic; Andreas R Luft; Mengia Rioult-Pedotti; Yi Zuo; Marta Zagrebelsky; Martin E Schwab
Journal:  J Neurosci       Date:  2014-06-25       Impact factor: 6.167

Review 8.  Nogo-A Antibodies for Progressive Multiple Sclerosis.

Authors:  Benjamin V Ineichen; Patricia S Plattner; Nicolas Good; Roland Martin; Michael Linnebank; Martin E Schwab
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

9.  Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice.

Authors:  Antonio Ortega-Alvaro; Auxiliadora Aracil-Fernández; María S García-Gutiérrez; Francisco Navarrete; Jorge Manzanares
Journal:  Neuropsychopharmacology       Date:  2011-03-23       Impact factor: 7.853

Review 10.  Perineuronal nets and schizophrenia: the importance of neuronal coatings.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2014-04-04       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.